CLOCK and cancer: Epigenetic clock DNAm metrics may be affected by the presence of cancer mutations in the germline, and thus show promise of potential clinical utility for assessment of relative risk related to imminent emergence of tumor lesions in otherwise healthy Lynch Syndrome-associated mutation carriers.